Tech Company M&A Transactions
Syntonix Pharmaceuticals Acquisition
Headquartered in Waltham, Syntonix Pharmaceuticals was acquired by Biogen. Biogen disclosed that the acquisition price was $120 million.
Transaction Overview
Company Name
Acquired By
Announced On
1/4/2007
Transaction Type
M&A
Amount
$120,000,000
M&A Terms
Upon completion, Biogen Idec will acquire all of the issued and outstanding shares of the capital stock of Syntonix for $40 million, payable at closing, and potential additional payments of up to $80 million upon the achievement of certain development milestones.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
9 Fourth Avenue
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Not Recorded
Overview
Syntonix is developing next generation biopharmaceuticals that enable better treatment options for patients with devastating chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Ripple
Browse more venture capital transactions:
Prev: 1/4/2007: Mochila venture capital transaction
Next: 1/4/2007: InvenSense venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs